# SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)

> **NCT05718232** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 136 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **PROCEDURE:** TACE
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT05718232
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-03
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718232, "SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05718232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*